153
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Serum Creatinine to Cystatin C Ratio is an Effective Indicator for Muscle Strength Decline in Men with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

, ORCID Icon, , , , , , , , , & show all
Pages 781-789 | Published online: 08 Apr 2022

References

  • Global Initiative for Chronic Obstructive Lung Disease GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD 2020. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2020.
  • Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi:10.7189/jogh.05.020415
  • World Health Organization. Projections of mortality and causes of death, 2016 and 2060. Available from: https://www.who.int/healthinfo/global_burden_disease/projections_method.pdf. Accessed December 26, 2021.
  • Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412. doi:10.1183/09031936.06.00025805
  • Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–888. doi:10.2147/COPD.S49621
  • Chen LK, Woo J, Assantachai P, et al. Asian Working Group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–307 e302. doi:10.1016/j.jamda.2019.12.012
  • Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601. doi:10.1093/ageing/afz046
  • Keogh E, Mark Williams E. Managing malnutrition in COPD: a review. Respir Med. 2021;176:106248. doi:10.1016/j.rmed.2020.106248
  • Volkert D. The role of nutrition in the prevention of sarcopenia. Wien Med Wochenschr. 2011;161(17–18):409–415. doi:10.1007/s10354-011-0910-x
  • Contreras-Bolivar V, Sanchez-Torralvo FJ, Ruiz-Vico M, et al. GLIM criteria using hand grip strength adequately predict six-month mortality in cancer inpatients. Nutrients. 2019;11(9):2043. doi:10.3390/nu11092043
  • Jeong M, Kang HK, Song P, et al. Hand grip strength in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:2385–2390. doi:10.2147/COPD.S140915
  • Shah S, Nahar P, Vaidya S, Salvi S. Upper limb muscle strength & endurance in chronic obstructive pulmonary disease. Indian J Med Res. 2013;138(4):492–496.
  • Ahmadi A, Mazloom Z, Eftekhari MH, et al. Muscle mass and function are related to respiratory function in chronic obstructive pulmonary disease. Med J Islam Repub Iran. 2021;35:34. doi:10.47176/mjiri.35.34
  • Turan Z, Ozyemisci Taskiran O, Erden Z, Kokturk N, Kaymak Karatas G. Does hand grip strength decrease in chronic obstructive pulmonary disease exacerbation? A cross-sectional study. Turk J Med Sci. 2019;49(3):802–808. doi:10.3906/sag-1811-22
  • Martinez CH, Diaz AA, Meldrum CA, et al. Handgrip strength in chronic obstructive pulmonary disease. associations with acute exacerbations and body composition. Ann Am Thorac Soc. 2017;14(11):1638–1645. doi:10.1513/AnnalsATS.201610-821OC
  • Holden M, Fyfe M, Poulin C, et al. Handgrip strength in people with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Phys Ther. 2021;101(6). doi:10.1093/ptj/pzab057
  • Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med. 1988;39:465–490. doi:10.1146/annurev.me.39.020188.002341
  • Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function–a review. Clin Chem Lab Med. 1999;37(4):389–395. doi:10.1515/CCLM.1999.064
  • Osaka T, Hamaguchi M, Hashimoto Y, et al. Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;139:52–58. doi:10.1016/j.diabres.2018.02.025
  • Fu X, Tian Z, Wen S, et al. A new index based on serum creatinine and cystatin C is useful for assessing sarcopenia in patients with advanced cancer. Nutrition. 2021;82:111032. doi:10.1016/j.nut.2020.111032
  • Lin YL, Chen SY, Lai YH, et al. Serum creatinine to cystatin C ratio predicts skeletal muscle mass and strength in patients with non-dialysis chronic kidney disease. Clin Nutr. 2020;39(8):2435–2441. doi:10.1016/j.clnu.2019.10.027
  • Yanishi M, Kinoshita H, Tsukaguchi H, et al. The creatinine/cystatin C ratio provides effective evaluation of muscle mass in kidney transplant recipients. Int Urol Nephrol. 2019;51(1):79–83. doi:10.1007/s11255-018-2015-6
  • Kashani K, Sarvottam K, Pereira NL, Barreto EF, Kennedy CC. The sarcopenia index: a novel measure of muscle mass in lung transplant candidates. Clin Transplant. 2018;32(3):e13182. doi:10.1111/ctr.13182
  • Tang T, Zhuo Y, Xie L, Wang H, Yang M. Sarcopenia index based on serum creatinine and cystatin C is associated with 3-year mortality in hospitalized older patients. Sci Rep. 2020;10(1):1260. doi:10.1038/s41598-020-58304-z
  • Hirai K, Tanaka A, Homma T, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease. Clin Nutr. 2021;40(3):1274–1280. doi:10.1016/j.clnu.2020.08.010
  • Puh U. Age-related and sex-related differences in hand and pinch grip strength in adults. Int J Rehabil Res. 2010;33(1):4–11. doi:10.1097/MRR.0b013e328325a8ba
  • Tan L, Li R, Hu X, et al. Serum creatinine/cystatin C ratio as a case-finding tool for low handgrip strength in Chinese middle-aged and older adults. Sci Rep. 2020;10(1):14028. doi:10.1038/s41598-020-71028-4
  • Warnken-Miralles MD, Lopez-Garcia F, Zamora-Molina L, Soler-Sempere MJ, Padilla-Navas I, Garcia-Pachon E. [Sarcopenia index in hospitalized patients with chronic obstructive pulmonary disease exacerbation]. Medicina. 2021;81(3):323–328. Spanish.
  • Amado CA, Garcia-Unzueta MT, Lavin BA, et al. The ratio serum creatinine/serum cystatin C (a surrogate marker of muscle mass) as a predictor of hospitalization in chronic obstructive pulmonary disease outpatients. Respiration. 2019;97(4):302–309. doi:10.1159/000494296
  • Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
  • Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.581
  • Pulmonary Function Professional Group. Pulmonary function test guide-lung volume test. Chin J Tuberc Respir. 2015;38(04):255–260. Chinese.
  • Hunter GR, Singh H, Carter SJ, Bryan DR, Fisher G. Sarcopenia and its implications for metabolic health. J Obes. 2019;2019:8031705. doi:10.1155/2019/8031705
  • Langen RC, Gosker HR, Remels AH, Schols AM. Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease. Int J Biochem Cell Biol. 2013;45(10):2245–2256. doi:10.1016/j.biocel.2013.06.015
  • Schaap LA, van Schoor NM, Lips P, Visser M. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the Longitudinal Aging Study Amsterdam. J Gerontol a Biol Sci Med Sci. 2018;73(9):1199–1204. doi:10.1093/gerona/glx245
  • Newman AB, Kupelian V, Visser M, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol a Biol Sci Med Sci. 2006;61(1):72–77. doi:10.1093/gerona/61.1.72
  • Lee CT, Wang PH. Handgrip strength during admission for COPD exacerbation: impact on further exacerbation risk. BMC Pulm Med. 2021;21(1):245. doi:10.1186/s12890-021-01610-7
  • Ichikawa T, Miyaaki H, Miuma S, et al. Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease. Biomed Rep. 2020;12(3):89–98. doi:10.3892/br.2020.1273
  • Chen L, Liu X, Wang Q, et al. Better pulmonary function is associated with greater handgrip strength in a healthy Chinese Han population. BMC Pulm Med. 2020;20(1):114. doi:10.1186/s12890-020-1155-5
  • Shin HI, Kim DK, Seo KM, Kang SH, Lee SY, Son S. Relation between respiratory muscle strength and skeletal muscle mass and hand grip strength in the healthy elderly. Ann Rehabil Med. 2017;41(4):686–692. doi:10.5535/arm.2017.41.4.686
  • Ferrari K, Goti P, Misuri G, et al. Chronic exertional dyspnea and respiratory muscle function in patients with chronic obstructive pulmonary disease. Lung. 1997;175(5):311–319. doi:10.1007/PL00007577
  • Vilaro J, Ramirez-Sarmiento A, Martinez-Llorens JM, et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med. 2010;104(12):1896–1902. doi:10.1016/j.rmed.2010.05.001
  • Piquet J, Chavaillon JM, David P, et al. High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J. 2013;42(4):946–955. doi:10.1183/09031936.00180312
  • Kashani KB, Frazee EN, Kukralova L, et al. Evaluating muscle mass by using markers of kidney function: development of the sarcopenia index. Crit Care Med. 2017;45(1):e23–e29. doi:10.1097/CCM.0000000000002013